Evaluation of CG-100 Intraluminal Bypass Device

Not Applicable

Recruiting

• Conditions: Colorectal Cancer
• Interventions: Device: CG-100 Intraluminal Bypass Device

• Registration Number: NCT05632744
• Lead Sponsor: Colospan Ltd.

Brief Summary

Evaluation of CG-100 Intraluminal Bypass device

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-11-08
• Study First Submitted QC: 2022-11-27
• Study First Posted: 2022-12-01
• Study Start: 2023-03-15
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-12
• Last Update Posted: 2024-02-14
• Primary Completion: 2024-06-15
• Study Completion: 2024-06-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CG-100 Intraluminal Bypass Device	CG-100 Intraluminal Bypass Device	Subjects will be treated with CG-100 Intraluminal Bypass Device

Primary Outcome Measures

Name	Time	Method
Safety of the CG-100 Intraluminal Bypass Device	10 days	Assessment of Serious Adverse Events

Secondary Outcome Measures

Name	Time	Method
Safety of the CG-100 Intraluminal Bypass Device	4 weeks	Assessment of Serious Adverse Events

Trial Locations

Locations (1)

Soroka Medical Center; 🇮🇱 Reẖovot, Israel